CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Gift Director gave 315,000 shares (gift)
- 4 Open-market sale Chief Financial Officer sold 14,950 shares at $40.10 ($599,495)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Financial Officer sold 7,500 shares at an average $40.17 ($301,260)
- 4 Open-market sale Chief Financial Officer sold 15,000 shares at an average $40.09 ($601,320)
- 4 Exercise or conversion Chief Financial Officer acquired 10,000 shares (option exercise)
- 4 Open-market sale SVP, Product Development & CTO sold 56,993 shares at an average $50.28 ($2,865,636)
- 4 Open-market sale Chief Financial Officer sold 14,806 shares at an average $50.07 ($741,352)
- 4 Open-market sale Director sold 24,800 shares at $50.11 ($1,242,728)
- 4 Open-market sale SVP, Product Development & CTO sold 5,637 shares at $50.00 ($281,850)
- 4 Open-market sale Chief Financial Officer sold 300 shares at $50.00 ($15,000)
- 4 Open-market sale Director sold 2,000 shares at $50.00 ($100,000)
- 5 Insider Annual Insider Trading Report
Page 10 of 22 · 435 filings